Phenylbutazone induces equine glandular gastric disease without decreasing prostaglandin E2 concentrations
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Veterinary Pharmacology and Therapeutics"
DOI: 10.1111/jvp.12464
Abstract: In equids, phenylbutazone at high doses induces gastric disease, primarily in the glandular portion of the stomach. However, the mechanism of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric disease in horses has yet to be determined. While… read more here.
Keywords: phenylbutazone; gastric disease; glandular gastric; treatment ... See more keywords
APTES-Modified SBA-15 as a Non-Toxic Carrier for Phenylbutazone
Sign Up to like & getrecommendations! Published in 2022 at "Materials"
DOI: 10.3390/ma15030946
Abstract: Improvement of the bioavailability of poorly soluble medicinal substances is currently one of the major challenges for pharmaceutical industry. Enhancing the dissolution rate of those drugs using novel methods allows to increase their bioavailability. In… read more here.
Keywords: aptes modified; phenylbutazone; dissolution rate; modified sba ... See more keywords